OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Leslie on Axi-Cel Vs SOC in Relapsed/Refractory Large B-Cell Lymphoma

January 7th 2022

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL

January 6th 2022

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

Dr. Randall on Preventing Early Failures With Osseointegrated Endoprostheses in Bone Sarcomas

January 6th 2022

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

January 6th 2022

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Dr. Koehne on Axi-Cel Vs Tisa-Cel in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

January 5th 2022

Guenther Koehne, MD, PhD, discusses the real-life study of CAR T-cell agents axicabtagene ciloleucel vs tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Heyman on the Evolution of BTK Inhibitors in Relapsed/Refractory MCL

January 5th 2022

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Mark on ​Questions Regarding Sequencing in Multiple Myeloma

January 5th 2022

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

January 5th 2022

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer

January 5th 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Dr. Burger on Choosing Frontline Therapy in CLL

January 5th 2022

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

January 5th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Dr. Tolaney on the Importance of Evaluating Enobosarm in ER+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

Dr. Posner on Leveraging Tipifarnib in HRAS-Mutant Head and Neck Cancer

January 4th 2022

Marshall Posner, MD, shares his clinical experience with the use of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Dr. Wirth on the Utility of Tipifarnib in Head and Neck Cancer

January 4th 2022

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Dr. Larocca on Treatment Considerations for Difficult-to-Treat, Relapsed/Refractory Myeloma

January 3rd 2022

Alessandra Larocca, MD, PhD, discusses the various factors to consider when selecting treatment for difficult-to-treat patients with relapsed/refractory multiple myeloma.

Dr. Monk on Remaining Unmet Needs in Recurrent Ovarian Cancer

January 3rd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

January 3rd 2022

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Dr. Kremyanskaya on the Next Steps of the MANIFEST Trial in Myelofibrosis

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Jain on the Push Toward Personalized Treatment Approaches in CRC With Liver Metastases

January 3rd 2022

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

January 3rd 2022

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

NEXT PAGE
PREVIOUS PAGE